Trial Readiness Report
This is an illustrative example of the report you receive — built for a fictional patient so you can see the structure before running your own. Every trial, NCT ID, and detail below is mock content for demonstration.
Editorial team
Written and fact-checked by the Clinical Trial Compass editorial team
Pending clinical review by a board-certified physician. Read our editorial standards →
Last updated June 6, 2026
Patient snapshot
Who this report was built for
A fictional 54-year-old with HER2-positive, Stage 2 breast cancer. These details shape which trials surface and why.
- Age
- 54
- Stage
- Stage 2 (T2 N1 M0)
- Biomarker
- HER2-positive, ER/PR-positive
- Prior treatment
- Surgery complete; considering adjuvant options
- Location
- Within 60 miles of Columbus, OH
- Other
- No prior trastuzumab; ECOG 0–1
At a glance
What the report found
“Worth discussing” does not mean you qualify. It means these studies are close enough to your snapshot to be worth raising with your doctor. Counts and details here are illustrative.
Trial matches
Trials worth discussing with your doctor
Each entry explains in plain English why it surfaced, what to confirm with the study team, the time commitment involved, and questions to bring to your appointments.
Adjuvant Trastuzumab Deruxtecan vs. Standard Therapy in Early-Stage HER2-Positive Breast Cancer
Why this may be relevant
This trial is testing a newer antibody-drug conjugate as an add-on after surgery for people whose tumours are HER2-positive and caught at an early stage — which lines up with the snapshot above. Because it's an adjuvant (post-surgery) study, it's aimed at lowering the chance the cancer comes back, not at treating advanced disease.
Eligibility factors to verify
You may meet some major criteria — confirm each one with the study team before assuming you qualify.
Likely fits if
- ✓Tumour is confirmed HER2-positive on a recent pathology report
- ✓Surgery to remove the tumour is already complete
- ✓You are generally up and about most of the day (ECOG 0–1)Worth confirming how the study measures this.
May rule you out if
- ✕You have already had trastuzumab or a similar HER2 drug
- ✕Known significant heart problemsThese drugs can affect heart function, so a heart scan is usually required first.
- ✕The cancer has spread beyond the breast and nearby lymph nodes
Trial burden — what taking part involves
- Visits
- Infusion every 3 weeks, plus periodic heart and imaging scans
- Duration
- About 12 months of active treatment, then follow-up visits
- Day-to-day
- Half-day infusion visits; bloodwork before each cycle
Safety context
Reported side effects in this drug class include nausea, fatigue, and — less commonly — lung inflammation. These are real-world safety signals, not proof of causation, and your study team will explain how they monitor for them.
Questions for your doctor
- •Given my pathology, is an adjuvant antibody-drug conjugate a reasonable option for me?
- •How would joining this trial change my standard treatment plan?
- •What heart monitoring would I need, and do I have any risk factors?
Questions for the coordinator
- •How is the comparison group treated — could I receive standard therapy instead of the new drug?
- •What does a typical treatment day look like, start to finish?
- •Who do I call if I have a side effect between visits?
Source: ClinicalTrials.gov record NCT05512345. Eligibility wording simplified from the registry; last updated 28 May 2026.
Neratinib Added to Standard HER2 Therapy for Hormone-Receptor-Positive, Node-Positive Breast Cancer
Why this may be relevant
This study looks at adding an oral HER2-targeted pill to standard therapy specifically for people whose cancer is both HER2-positive and hormone-receptor-positive with lymph-node involvement — which matches the ER/PR-positive, node-positive details in the snapshot. It may be relevant if you and your doctor are weighing how aggressively to treat after surgery.
Eligibility factors to verify
You may meet some major criteria — confirm each one with the study team before assuming you qualify.
Likely fits if
- ✓Cancer is HER2-positive and hormone-receptor (ER or PR) positive
- ✓At least one nearby lymph node was involved
- ✓You can take a daily oral medication reliably
May rule you out if
- ✕Ongoing significant digestive problemsDiarrhoea is a common side effect of this drug, so the team screens for this.
- ✕You are already on another investigational drug
Trial burden — what taking part involves
- Visits
- Mostly oral medication at home, with monthly check-in visits
- Duration
- Up to 12 months of the study drug
- Day-to-day
- Daily pills; a side-effect diary; monthly bloodwork
Safety context
Diarrhoea is the most frequently reported side effect for this medication, and there are established ways to manage it. These are real-world safety signals, not proof of causation — ask the team how they prevent and treat it.
Questions for your doctor
- •Does adding an oral HER2 drug make sense given my hormone-receptor status?
- •How would the side effects fit around my daily life and work?
- •Is there evidence this lowers recurrence risk for someone like me?
Questions for the coordinator
- •What support is offered to manage digestive side effects?
- •How often would I actually need to come in versus manage at home?
- •What happens if I miss a dose?
Source: ClinicalTrials.gov record NCT05887766. Eligibility wording simplified from the registry; last updated 19 May 2026.
Exercise and Lifestyle Program During Adjuvant Therapy for Early-Stage Breast Cancer
Why this may be relevant
Not every trial is about a new drug. This supportive-care study tests whether a structured exercise and lifestyle program during treatment improves energy and quality of life. It could run alongside whatever treatment you and your doctor choose, which is why it appears here as a lower-burden option to discuss.
Eligibility factors to verify
You may meet some major criteria — confirm each one with the study team before assuming you qualify.
Likely fits if
- ✓Currently receiving or about to start adjuvant therapy
- ✓Cleared by your doctor to take part in light-to-moderate exercise
May rule you out if
- ✕A condition that makes supervised exercise unsafeYour own doctor's sign-off is part of joining.
Trial burden — what taking part involves
- Visits
- Weekly virtual coaching plus a monthly in-person assessment
- Duration
- 16 weeks
- Day-to-day
- About 2–3 guided sessions per week, mostly from home
Safety context
Supportive-care studies like this generally carry low physical risk, but any exercise program should be cleared by your care team first. Reported issues are typically minor (soreness, fatigue) and are real-world signals, not proof of causation.
Questions for your doctor
- •Is it safe for me to start a structured exercise program during treatment?
- •Could this help with the fatigue I'm likely to experience?
Questions for the coordinator
- •Can the sessions be done entirely from home if I'm having a hard week?
- •What happens to my participation if my treatment schedule changes?
Source: ClinicalTrials.gov record NCT06034521. Eligibility wording simplified from the registry; last updated 2 Jun 2026.
Tucatinib Combination Therapy for HER2-Positive Breast Cancer Following Surgery
Why this may be relevant
This combination study is further away and is currently enrolling by invitation, meaning sites generally approach eligible patients rather than taking open sign-ups. It's included so you can ask your doctor whether a referral to this kind of study would make sense for your situation.
Eligibility factors to verify
You may meet some major criteria — confirm each one with the study team before assuming you qualify.
Likely fits if
- ✓HER2-positive cancer treated with surgery
- ✓Referred or identified by a participating cancer centre
May rule you out if
- ✕Significant liver function problems
- ✕Unable to travel to the study site for required visits
Trial burden — what taking part involves
- Visits
- Combination of oral drugs and clinic visits every few weeks
- Duration
- Approximately 12 months
- Day-to-day
- Travel to Cincinnati for assessments; daily oral medication
Safety context
Reported side effects for this combination include diarrhoea and changes in liver blood tests, monitored closely during the study. These are real-world safety signals, not proof of causation.
Questions for your doctor
- •Would a referral to a larger cancer centre be worthwhile for me?
- •Is the extra travel justified by what this trial offers over standard care?
Questions for the coordinator
- •How does the 'enrolling by invitation' process work — could I be considered?
- •Is any travel or lodging support available?
Source: ClinicalTrials.gov record NCT05729004. Eligibility wording simplified from the registry; last updated 11 May 2026.
Important — please read
This is an illustrative examplebuilt around a fictional patient. The trials, NCT IDs, distances, and eligibility details are mock content created to show the report's structure. They are not real listings and must not be used to make any decision.
Nothing here is medical advice. A Trial Readiness Report surfaces and translates public information — it does not interpret it for your specific situation. Matching a snapshot does not mean you qualify: you may meet some major criteria, but you must confirm everything with the study team and your own doctor.
Safety information reflects real-world safety signals, not proof of causation. Always review the original ClinicalTrials.gov record (linked by NCT ID) and the source last-updated date before acting.
Run your own report
Answer a few questions about your condition and we'll build a Trial Readiness Report like this one — with real, current trials and plain-English guidance to bring to your care team.
Free to run. Data current as of 6 Jun 2026.